Published in Cancer Immunol Immunother on April 25, 2013
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res (2014) 0.94
Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ. Clin Cancer Res (2014) 0.93
Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol (2014) 0.86
Janus-faced tumor microenvironment and redox. Antioxid Redox Signal (2014) 0.85
Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) (2014) 0.84
The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther (2015) 0.83
HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response. Viruses (2015) 0.82
Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther (2014) 0.81
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One (2015) 0.79
Oncolytic viruses: focusing on the tumor microenvironment. Cancer Gene Ther (2015) 0.77
DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect. Oncol Lett (2017) 0.75
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci Rep (2016) 0.75
A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner. Front Cell Infect Microbiol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity (1996) 3.18
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 2.59
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79
Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Res Hum Retroviruses (1993) 1.46
Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med (1999) 1.45
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol (1997) 1.36
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res (2007) 1.12
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 1.11
The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother (2009) 1.06
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 1.03
Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine (1996) 1.00
CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther (2003) 0.97
The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep (2009) 0.88
Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. J Hepatol (2000) 0.80
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. Cell (2010) 2.32
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol (2008) 1.54
Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol (2003) 1.40
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist (2006) 1.40
Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol Oncol (2002) 1.38
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. BMC Gastroenterol (2006) 1.23
Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2008) 1.22
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 1.19
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. Am J Obstet Gynecol (2004) 1.17
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol (2009) 1.14
Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther (2012) 1.13
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol (2013) 1.10
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother (2012) 1.10
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Gene therapy for ovarian cancer. Curr Oncol Rep (2006) 1.08
Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther (2006) 1.08
A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther (2006) 1.08